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Disruption of pulmonary valve integrity after Tetralogy of Fallot repair often results in a cascade of hemodynamic
and electrophysiological abnormalities. Here we report an uncommon case of severe pulmonary regurgitation with
concomitant rheumatic mitral stenosis diagnosed 25 years after primary Tetralogy of Fallot repair. A 33-year-old
man presented with symptomatic palpitation and exercise intolerance and was treated successfully with
pulmonary and mitral valve replacement, after which his symptoms improved dramatically.
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Tetralogy of Fallot (TOF) is the most common cyanotic
congenital heart defect [1]. The number of adults with a
repaired TOF is large. Pulmonary regurgitation (PR) is
the major long-term issue in adults after TOF repair [2].
However, few patients have both PR and rheumatic
stenosis after repaired TOF, and cases of patients who
underwent both pulmonary valve replacement (PVR) for
PR after repaired TOF and mitral valve replacement
(MVR) are rare. Here we report a case with both PR
after repaired TOF and rheumatic mitral stenosis and
discuss the choice of prosthesis during PVR and MVR.Case presentation
A 33-year-old man was admitted to our hospital with
palpitation and lower extremity edema after activity. Six
months prior, he started feeling palpitations and more
tired than usual after activity. These symptoms became
aggravated after he developed a common cold 4 months
prior to presentation. He also complained of lower
extremity edema and difficulty laying down at night. He
was treated with medicines including digoxin and
furosemide prior to admission to our ward. The patient* Correspondence: edwarddian@163.com
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however, the surgery data were lost and he had no regu-
lar follow-up.
On admission, the patient’s heart rate was 67 beats/min,
blood pressure was 119/79 mmHg, and respirations were
12 per minute with oxygen saturations around 99% on
room air. Under cardiac auscultation, the cardiac rhythm
was regular; a diastolic murmur at the apex was heard.
Blood chemistry was normal. Echocardiography showed
an acceleration of forward blood flow and regurgitation in
the pulmonary valve (moderate-severe) (Figure 1), mitral
valve stenosis (severe), and tricuspid regurgitation (mild),
while a detailed assessment revealed that the pulmonary
valve was short and curly. Electrocardiography showed
sinus rhythm and a right bundle branch block. Magnetic
resonance imaging showed thickening and opening re-
striction of the mitral valve (Figure 2) as well as mild
regurgitation in the tricuspid and aortic valves. Computed
tomography showed an increase in texture within the
lungs and an enlarged heart.
The patient was scheduled for mitral valve and PVR
surgery after diagnosis. During the procedure, we found
that the mitral valve was significantly thickened, suggest-
ive of rheumatic heart disease (RHD). The valve leaflets
of the pulmonary valve were significantly shrunken and
difficult to repair. The patient underwent a mitral valve
replacement with a mechanical valve, and a PVR with a
bioprosthetic valve. The patient began to take warfarinhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Echocardiogram showing moderate to severe regurgitation within the pulmonary valve.
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adjusted according to the International Normalized
Ratio (INR) level, which was maintained at about
2.5. A postoperative X-ray showed that the prostheses
were well placed (Figure 3). The pathological changes
suggestive of RHD were verified by histopathological
examination. The patient recovered well and was discharged.
On an outpatient visit 6 months after the operation, the
patient was graded New York Heart Association functional
class I.
Discussion
TOF is the most common cyanotic congenital heart
defect. Patients usually undergo complete repair at
4–6 months of age in most centers [1]. However,Figure 2 Magnetic resonance image showing thickening and opening resproblems including PR and recurrent or residual pul-
monary stenosis are usually observed in young adults
despite surgical repair [1]. Among them, chronic PR is
the most common long-term issue in adults after TOF
repair [2]. During TOF repair, a transannular incision is
usually made to relieve the right ventricular outflow
stenosis. Progressive PR may be caused by this repair
over a long periods [3]. Severe chronic PR after TOF
repair can lead right ventricular dilation, which is
associated with right heart failure, exercise intolerance,
ventricular arrhythmias, and sudden cardiac death
[3,4].
PVR is the most frequent reoperation performed in
adults to resolve PR [3,5]. By attenuating the right ven-
tricle volume overload, PVR can lead to improved righttriction of the mitral valve.
Figure 3 Postoperative X-ray image showing the bioprosthetic valve in the pulmonary valve position and the mechanical valve at the mitral
valve position.
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clinical symptoms [2,3]. Since a mechanical valve can
increase the risk for valve thrombosis, it is not widely
used in PVR; rather, the most commonly used valve for
PVR is bioprosthetic pulmonary valve [2-5]. However,
the life expectancy of the bioprosthetic valve is limited
because of issues such as stenosis and calcification.
Therefore, we should consider the re-operation rate
when choosing the bioprosthetic valve [2-4]. Although
the lifespans of different valve types is controversial,
Jang et al. reported an acceptable rate of freedom from
reoperation for bioprosthetic valves for PVR during the
10-year follow-up period [3].
RHD remains a major health issue in developing coun-
tries, where it is the major cause of the cardiovascular
mortality and morbidity in young people with a mortal-
ity as high as 250000 per year [6]. The main pathological
characteristic of RHD is valvular damage, while myocar-
ditis and pericardial are frequently involved [7]. Mitral
valve stenosis is the most common valvular lesion in pa-
tients with RHD [6]. When the valvular lesions are severe
and patients become symptomatic, surgery including mi-
tral valve repair or mitral valve replacement is considered
[6]. Mitral valve replacement is warranted when thevalvular lesions are too severe to repair. The choice of
prosthesis for valve replacement depends on patient char-
acteristics such as the age [6]. According to the guideline
from American College of Cardiology/American Heart
Association, mechanical valves are more suitable for
patients < 65 years old [8]. Mechanical valves are
also recommended for young adults with MVR by the
European Society of Cardiology and the European
Association for Cardio-Thoracic Surgery guideline [9].
In addition, Kaneko et al compared the outcomes of
mechanical valve versus bioprosthetic valve in patients
< 65 years with MVR. Their results showed longer survival
of patients with MVR who received a mechanical valve
compared to bioprosthetic valve, which reconfirms the
recommendation of mechanical valve use for MVR in
patients < 65 years old [10].
Both PR after repaired TOF and rheumatic mitral
stenosis are common heart disease, and there are a
number of studies about the treatment or valve choice
for each disease. However, PR after TOF repair and
rheumatic mitral stenosis in the same patient is rare,
and few patients have undergone both PVR for PR after
TOF repair and mitral valve replacement. Therefore,
how to select the appropriate valves remains unknown.
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PVR to decrease the patient’s risk of anti-coagulation
and the mechanical valve was chosen for the MVR to
decrease the risk of reoperation considering that the pa-
tient was 33 years old. However, we are not sure whether
our choice in valves could increase the risk of complica-
tions caused by anti-coagulation associated with the
mechanical valve or the reoperation rate associated with
the bioprosthetic valve. The appropriate INR range for
this kind of patient is also still uncertain. Further long-
time follow-up is needed to clarify these details.
Conclusions
Patients who undergo both pulmonary valve and mitral
valve replacements after TOF repair are rare. While choos-
ing prostheses for such patients, clinicians should consider
patient characteristics and balance the risks and benefits of
each kind of prosthesis.
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